
Vanessa L. Ford
Supervisory Patent Examiner (ID: 3360, Phone: (571)272-0857 , Office: P/1646 )
| Most Active Art Unit | 1645 |
| Art Unit(s) | 1645, 1646, 1674 |
| Total Applications | 544 |
| Issued Applications | 158 |
| Pending Applications | 78 |
| Abandoned Applications | 314 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20599039
[patent_doc_number] => 20260077042
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-03-19
[patent_title] => METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 19/389528
[patent_app_country] => US
[patent_app_date] => 2025-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34690
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19389528
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/389528 | METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS | Nov 13, 2025 | Pending |
Array
(
[id] => 20151568
[patent_doc_number] => 20250251406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-07
[patent_title] => BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 19/187615
[patent_app_country] => US
[patent_app_date] => 2025-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16992
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19187615
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/187615 | BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS | Apr 22, 2025 | Pending |
Array
(
[id] => 20608318
[patent_doc_number] => 12583906
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-24
[patent_title] => Actrii proteins and use in treating post-capillary pulmonary hypertension
[patent_app_type] => utility
[patent_app_number] => 18/953973
[patent_app_country] => US
[patent_app_date] => 2024-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 55
[patent_no_of_words] => 66090
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18953973
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/953973 | Actrii proteins and use in treating post-capillary pulmonary hypertension | Nov 19, 2024 | Issued |
Array
(
[id] => 19543171
[patent_doc_number] => 20240360207
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST
[patent_app_type] => utility
[patent_app_number] => 18/401117
[patent_app_country] => US
[patent_app_date] => 2023-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18401117
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/401117 | METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONIST | Dec 28, 2023 | Abandoned |
Array
(
[id] => 19112799
[patent_doc_number] => 20240124549
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
[patent_app_type] => utility
[patent_app_number] => 18/393269
[patent_app_country] => US
[patent_app_date] => 2023-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16969
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393269
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/393269 | IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1 | Dec 20, 2023 | Pending |
Array
(
[id] => 19318339
[patent_doc_number] => 20240239882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15)
[patent_app_type] => utility
[patent_app_number] => 18/392926
[patent_app_country] => US
[patent_app_date] => 2023-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18392926
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/392926 | MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) | Dec 20, 2023 | Abandoned |
Array
(
[id] => 19345290
[patent_doc_number] => 20240254253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => ANTI-uPAR ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/535395
[patent_app_country] => US
[patent_app_date] => 2023-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42553
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 1210
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18535395
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/535395 | ANTI-uPAR ANTIBODIES AND USES THEREOF | Dec 10, 2023 | Pending |
Array
(
[id] => 19248768
[patent_doc_number] => 20240199755
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE
[patent_app_type] => utility
[patent_app_number] => 18/534506
[patent_app_country] => US
[patent_app_date] => 2023-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36587
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18534506
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/534506 | ANTAGONISTS AND AGONISTS OF THE TRANSFERRIN RECEPTOR-2 FOR USE IN THE TREATMENT OF DISEASES OF THE BONE | Dec 7, 2023 | Pending |
Array
(
[id] => 18939642
[patent_doc_number] => 20240034781
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA
[patent_app_type] => utility
[patent_app_number] => 18/483270
[patent_app_country] => US
[patent_app_date] => 2023-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18483270
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/483270 | HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA | Oct 8, 2023 | Pending |
Array
(
[id] => 19018931
[patent_doc_number] => 20240075102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 18/355108
[patent_app_country] => US
[patent_app_date] => 2023-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12252
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18355108
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/355108 | Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof | Jul 18, 2023 | Pending |
Array
(
[id] => 19142183
[patent_doc_number] => 20240141007
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => ENGINEERED CLEAVABLE CARRIERS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/352762
[patent_app_country] => US
[patent_app_date] => 2023-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63988
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18352762
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/352762 | ENGINEERED CLEAVABLE CARRIERS AND METHODS OF USE THEREOF | Jul 13, 2023 | Pending |
Array
(
[id] => 19097799
[patent_doc_number] => 20240117027
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFICALLY ANTAGONIZING GDF8 AND OR ACTIVIN A
[patent_app_type] => utility
[patent_app_number] => 18/135608
[patent_app_country] => US
[patent_app_date] => 2023-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18135608
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/135608 | COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFICALLY ANTAGONIZING GDF8 AND OR ACTIVIN A | Apr 16, 2023 | Pending |
Array
(
[id] => 18437452
[patent_doc_number] => 20230184747
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => T CELL-BASED METHODS FOR PREDICTING POLYPEPTIDE IMMUNOGENICITY
[patent_app_type] => utility
[patent_app_number] => 18/104825
[patent_app_country] => US
[patent_app_date] => 2023-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -102
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18104825
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/104825 | T CELL-BASED METHODS FOR PREDICTING POLYPEPTIDE IMMUNOGENICITY | Feb 1, 2023 | Pending |
Array
(
[id] => 18596060
[patent_doc_number] => 20230270851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/057637
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29085
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057637
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/057637 | METHODS FOR THE TREATMENT OF IDIOPATHIC ORBITAL INFLAMMATION AND RELATED CONDITIONS | Nov 20, 2022 | Abandoned |
Array
(
[id] => 18536105
[patent_doc_number] => 20230241192
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/054691
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054691
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054691 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Nov 10, 2022 | Pending |
Array
(
[id] => 18955567
[patent_doc_number] => 20240043894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => PRODUCTION OF NMN AND ITS DERIVATIVES VIA MICROBIAL PROCESSES
[patent_app_type] => utility
[patent_app_number] => 18/052595
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10466
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052595
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052595 | PRODUCTION OF NMN AND ITS DERIVATIVES VIA MICROBIAL PROCESSES | Nov 3, 2022 | Abandoned |
Array
(
[id] => 18649472
[patent_doc_number] => 20230295285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT
[patent_app_type] => utility
[patent_app_number] => 17/939634
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10078
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939634
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/939634 | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT | Sep 6, 2022 | Pending |
Array
(
[id] => 18299810
[patent_doc_number] => 20230109496
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/929799
[patent_app_country] => US
[patent_app_date] => 2022-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40963
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929799
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/929799 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | Sep 5, 2022 | Pending |
Array
(
[id] => 18240937
[patent_doc_number] => 20230073248
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE IN TRANSPLANTATION RECIPIENTS
[patent_app_type] => utility
[patent_app_number] => 17/820808
[patent_app_country] => US
[patent_app_date] => 2022-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820808 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE IN TRANSPLANTATION RECIPIENTS | Aug 17, 2022 | Pending |
Array
(
[id] => 18056507
[patent_doc_number] => 20220387593
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1
[patent_app_type] => utility
[patent_app_number] => 17/887856
[patent_app_country] => US
[patent_app_date] => 2022-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19841
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17887856
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/887856 | METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1 | Aug 14, 2022 | Abandoned |